130 related articles for article (PubMed ID: 6727389)
1. Improved tissue perfusion during pressure-regulated hyperthermic regional isolated perfusion in dogs.
Fontijne WP; de Vries J; Mook PH; Elstrodt JM; Oosterhuis JW; Schraffordt Koops H; Oldhoff J; Wildevuur CR
J Surg Oncol; 1984 May; 26(1):69-76. PubMed ID: 6727389
[TBL] [Abstract][Full Text] [Related]
2. Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. A clinical study.
Fontijne WP; Mook PH; Koops HS; Oldhoff J; Wildevuur CR
Cancer; 1985 Apr; 55(7):1455-61. PubMed ID: 3978538
[TBL] [Abstract][Full Text] [Related]
3. Isolated hindlimb perfusion in dogs: the effect of perfusion pressures on the oxygen supply (ptO2 histogram) to the skeletal muscle.
Fontijne WP; Mook PH; Elstrodt JM; Schraffordt Koops H; Oldhoff J; Wildevuur CR
Surgery; 1985 Mar; 97(3):278-84. PubMed ID: 3975848
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic regional perfusion using membrane- instead of bubble-oxygenators. An experimental and clinical study.
van Os J; Schraffordt Koops H; Oldhoff J; Wildevuur CR
J Cardiovasc Surg (Torino); 1989; 30(4):523-32. PubMed ID: 2777859
[TBL] [Abstract][Full Text] [Related]
5. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.
Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H
Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699
[TBL] [Abstract][Full Text] [Related]
6. Renal function in cancer patients treated with hyperthermic isolated limb perfusion with recombinant tumor necrosis factor-alpha and melphalan.
Zwaveling JH; Hoekstra HJ; Maring JK; v Ginkel RJ; Schraffordt Koops H; Smit AJ; Girbes AR
Nephron; 1997; 76(2):146-52. PubMed ID: 9200405
[TBL] [Abstract][Full Text] [Related]
7. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
Kettelhack C; Hohenberger P; Schlag PM
Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
[TBL] [Abstract][Full Text] [Related]
8. [O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan].
Haier J; Hohenberger P; Beck K; Schlag PM
Langenbecks Arch Chir; 1997; 382(3):128-33. PubMed ID: 9324610
[TBL] [Abstract][Full Text] [Related]
9. Hyperthermic isolated limb perfusion with cis-diamminedichloro-platinum. II. An experimental study in dogs with a balloon-occlusion technique for repeated high-dose treatment.
Wessalowski R; Wilhelm M; Torsello S; Sager M; Güttler J; Jürgens H; Göbel U
Med Pediatr Oncol; 1994; 22(6):393-7. PubMed ID: 8152401
[TBL] [Abstract][Full Text] [Related]
10. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique.
Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M
Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854
[TBL] [Abstract][Full Text] [Related]
11. Circuit and protocol for hypoxic hyperthermic isolated limb perfusion to treat malignant melanoma.
Innet LM; Haripershad V; Van Den Berg J; Cooper L
Perfusion; 2001 Jul; 16(4):325-30. PubMed ID: 11486853
[TBL] [Abstract][Full Text] [Related]
12. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
13. Autoregulation of hind-limb blood flow in conscious dogs.
Britton SL; Metting PJ; Ronau TF; Strader JR; Weldy DL
J Physiol; 1985 Nov; 368():409-22. PubMed ID: 2867218
[TBL] [Abstract][Full Text] [Related]
14. Technical aspects of isolation extremity perfusion: experimental studies and clinical experience.
Ghussen F; Krüger I
J Invest Surg; 1989; 2(4):487-96. PubMed ID: 2518674
[TBL] [Abstract][Full Text] [Related]
15. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J
Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic regional perfusion with melphalan and a combination of melphalan and actinomycin D in the treatment of locally metastasized malignant melanomas of the extremities.
Martijn H; Oldhoff J; Koops HS
J Surg Oncol; 1982 May; 20(1):9-13. PubMed ID: 7078190
[TBL] [Abstract][Full Text] [Related]
17. The limit of hyperthermic strain on skeletal muscle tissue during regional perfusion.
Ghussen F; Isselhard W
Res Exp Med (Berl); 1984; 184(2):115-23. PubMed ID: 6433411
[TBL] [Abstract][Full Text] [Related]
18. Desflurane as a marker of limb-to-systemic leak during hyperthermic isolated limb perfusion.
Stanley G; Sundarakumaran R; Crowley R; Kavanah M
Anesthesiology; 2000 Aug; 93(2):574-6. PubMed ID: 10910485
[No Abstract] [Full Text] [Related]
19. Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb.
Huber R; Krüger I; Kuper K; Huber PM; Pichlmaier H
Am J Surg; 1995 Oct; 170(4):345-52. PubMed ID: 7573726
[TBL] [Abstract][Full Text] [Related]
20. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
